

He participated to the creation of 4 start-ups. In addition, he is an active member of the Scientific Advisory Boards for 3 start-ups such as Urodelia and Beta Innov. With Nutriprevent, he developed programs on microbiota modulation through preventive nutrition particularly focused on inflammatory process.

With E-Sana as a co-founder with Pr Kalle Levon (Polytechnic Institute of NYU, Brooklyn, USA) and Césaire Massart, he participates to new programs based on innovative technology for tests including in-Home and biological monitoring, with dynamic follow-up. Nowadays, based on different patents on NK cells from Umbilical Cord Blood, he participates to new therapeutic strategies, including vaccine programs developed by URODELIA Inc. France).

A new bio-clinical platform for patients is developed with different Healthcare centers.

Dr Jean-François Rossi has over 30 years of experience in medicine and was certified in Rheumatology, Medical Oncology, Hematology, Immunology and Internal Medicine. He received his MD and PhD degrees in Hematology Immunology at the University of Montpellier and had post-doc at the Universities of Arizona (Tucson) and San Antonio (Texas) in the domain of multiple myeloma and bone research.

He was associate professor at the University of Suzhou (China) for more than 10 years. He is member of 7 international scientific societies and the Scientific Advisory Board of the Castleman Disease Collaborative Network (CDCN). Beginning at the Internal Medicine department, he was in charge of Medical Oncology for 5 years in Montpellier Cancer Center. Then, he became the head of the Hematology Department during 14 years and he developed 1) with Professor Bernard Klein the Biotherapy Saint-Eloi site (Immunotherapy Regenerative Medicine (Chu/Inserm/ University), 2) wellbeing concept using Art as a language for coming back to normal life with a "COMMANDE Publique d'Etat".

He was granted 3 patents and has 195 scientific PUBMED publications. He is particularly active in Immunotherapy for cancer and programs on crossed information analysis developing decision algorithms including epigenetics with microbiota and nutrition influence. He participated or activated different clinical or bio-clinical research programs with pharmaceutical companies (more than 150) or with academic institutes (national or international, including CliNK, from EEC on NK Lymphocytes). He obtained an AWARD from the AMERICAN ASSOCIATION for CANCER RESEARCH on April 2017 for his work on inflammatory process and interleukin 6 (<http://aacrjournals.org/content/j-f-rossi-bio> and The Best of the AACR Journals).

He was a consultant for different BIG PHARMA for more than 20 years, including Celgene, Roche, J&J (Centocor) for siltuximax development, Serono Merck for TACI-Ig FC5, Innate Pharma for IPH1101, LFB for the anti-CD20 LFB-R603, Petrovax Pharm LLC for polyoxidinium (ongoing), in-home biology for Horiba Medical and for Biotherapy with Marc Cluzel when he was the General Director of Sanofi Research.